GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (STU:AWY0) » Definitions » Net Cash per Share

Percheron Therapeutics (STU:AWY0) Net Cash per Share : €0.01 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Percheron Therapeutics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Percheron Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 was €0.01.

The historical rank and industry rank for Percheron Therapeutics's Net Cash per Share or its related term are showing as below:

STU:AWY0' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.52   Med: 4.31   Max: 19.5
Current: 4.15

During the past 13 years, the highest Price-to-Net-Cash Ratio of Percheron Therapeutics was 19.50. The lowest was 1.52. And the median was 4.31.

STU:AWY0's Price-to-Net-Cash is ranked better than
54.37% of 263 companies
in the Drug Manufacturers industry
Industry Median: 8.28 vs STU:AWY0: 4.15

Percheron Therapeutics Net Cash per Share Historical Data

The historical data trend for Percheron Therapeutics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics Net Cash per Share Chart

Percheron Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.02 0.01 -

Percheron Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 0.01 0.01 -

Competitive Comparison of Percheron Therapeutics's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Percheron Therapeutics's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Percheron Therapeutics's Price-to-Net-Cash falls into.



Percheron Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Percheron Therapeutics's Net Cash per Share for the fiscal year that ended in Jun. 2023 is calculated as

Net Cash per Share (A: Jun. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(6.794-1.776-0)/669.315
=0.01

Percheron Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(10.553-2.167-0)/901.545
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Percheron Therapeutics  (STU:AWY0) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Percheron Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Percheron Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Percheron Therapeutics Business Description

Traded in Other Exchanges
Address
14 Wallace Avenue, LEVEL 1, Toorak, VIC, AUS, 3142
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.

Percheron Therapeutics Headlines

No Headlines